We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Desvenlafaxine in Opioid-Dependent Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02200406
Recruitment Status : Completed
First Posted : July 25, 2014
Last Update Posted : October 23, 2020
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Background: Although substitution therapy has been shown to be highly effective to retain opioid-dependent patients in treatment and reduce drug use, this population is afflicted by numerous conditions including depression. Unfortunately, studies published thus far have reported inconsistent or no difference in response between placebo therapy and antidepressants such as selective serotonin reuptake inhibitors. Objective: To assess the feasibility of Desvenlafaxine (DESV) administration among opioid-dependent subjects and explore its effect on depressive symptoms. Methods: Open-label pilot trial of 8 weeks of DESV 50-100 mg/day in 20 methadone-maintained individuals with comorbid depressive symptoms at the Centre hospitalier de l'Université de Montréal. Significance: This pilot study will lay down the foundation on which a larger multisite clinical trial could be conducted to examine DESV as new treatment for opioid-dependent population with comorbid depression.

Condition or disease Intervention/treatment Phase
Depression Opioid Dependence Methadone Treatment Drug: Desvenlafaxine Phase 4

Detailed Description:

To assess the feasibility, tolerability and acceptability of 8 weeks of Desvenlafaxine (DESV) administration among opioid-dependent subjects in a methadone-maintenance program, we will collect detailed information on compliance to DESV treatment, side effects, methadone plasma levels, methadone dose changes and QTc measures.

To explore the effects of DESV on depressive symptoms among opioid-dependent subjects on methadone-maintenance treatment. The severity and symptoms of depression will be evaluated by using the MADRS, the HRDS, and the CGI scale.

To explore the effects of DESV on substance use, anxiety, craving, quality of life and suicidal risk.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression
Study Start Date : July 2014
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Desvenlafaxine
  • Open-label pilot study
  • Desvenlafaxine will be administered during 56 consecutive days
  • Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks.
 Drug: Desvenlafaxine
All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
Other Name: PRISTIQ


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Tolerability: Systematic Assessment for Treatment Emergent Events (SAFTEE) [ Time Frame: 8 weeks ]
    Safety and adverse effects with the Systematic Assessment for Treatment Emergent Events (SAFTEE)


Secondary Outcome Measures :
  1. effect of Desvenlafaxine on depressive symptoms [ Time Frame: 8 weeks ]
    Responders will be determined by a 50% reduction in (Hamilton Depression Rating Scale) HAM-D scores, and remitters will be determined based on scores of ≤7.

  2. effect of Desvenlafaxine on depressive symptoms [ Time Frame: 8 weeks ]
    Responders will be determined by a 50% reduction in the Montgomery-Asberg Depression Scale (MADRS) scores, and remitters will be determined based on scores of 10.

  3. Response to treatment [ Time Frame: 8 weeks ]
    A favorable response will be defined as a score of 1 or 2 (very much or much improved) on the Clinical Global Impression CGI-I subscale

  4. Feasibility: Proportion of persons screened who are eligible and enrolled [ Time Frame: Baseline ]
    Proportion of persons screened who are eligible and enrolled

  5. Treatment adherence [ Time Frame: 8 weeks ]
    Compliance will be evaluated at each in-person follow-up visit. Treatment adherence will be calculated as the total number of tablets dispensed minus the number returned, divided by the total number of tablets dispensed

  6. Effect of Desvenlafaxine administration on QT/QTc interval prolongation [ Time Frame: 4 weeks ]
    It will be assessed by electrocardiograms (upper limit for safety should be 500ms).

  7. Feasibility: Proportion of scheduled study visits completed and biological samples collected [ Time Frame: 8 weeks ]
    Proportion of scheduled study visits completed and biological samples collected

  8. Potential for drug interactions between methadone and antidepressants - Effect of Desvenlafaxine on methadone serum level (pharmacokinetic variability) [ Time Frame: 4 weeks ]
    Change from baseline in methadone serum level. We will assessed the methadone serum level at baseline and after a month of treatment.

  9. Methadone dose adjustments [ Time Frame: 2 - 4 weeks ]
    Change from baseline in methadone dose. Each dose adjustment occurring during the trial will be noted at each follow-up visit


Other Outcome Measures:
  1. Substance use [ Time Frame: 8 weeks ]
    number of days of substance use as assessed with The Time Line Follow-Back (TFLB), urine-drug testing and alcohol-breathalyzer testing.

  2. Effect of Desvenlafaxine on anxiety [ Time Frame: 8 weeks ]
    Change from Baseline in anxiety and mood. It will be assessed with the Hamilton Anxiety Rating Scale (HAM-A)

  3. Effect of Desvenlafaxine on blood pressure and heart rate [ Time Frame: 8 weeks ]
    Change from Baseline in Systolic Blood Pressure and heart rate

  4. Effect of Desvenlafaxine on opioid craving [ Time Frame: 8 weeks ]
    Assessed with the abbreviated Heroin Craving Questionnaire (HCQ) - Change from Baseline in Craving.

  5. Effect of Desvenlafaxine on quality of life [ Time Frame: 8 weeks ]
    Change from baseline in Quality of life. It will be assessed with the World Health Organization Quality of Life questionnaire (WHOQOL-BREF)

  6. Effect of Desvenlafaxine on disability [ Time Frame: 8 weeks ]
    Change from baseline in disability. It will be assessed with the Sheehan Disability Scale (SDS)

  7. Effect of Desvenlafaxine on suicidal behaviour [ Time Frame: 8 weeks ]
    Change from Baseline in suicidal behaviour. It will be assessed with the Columbia-Suicide Severity Rating Scale (CSSRS)

  8. Effect of Desvenlafaxine on testosterone level [ Time Frame: 4 weeks ]
    Change from Baseline in testosterone.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DSM-IV-TR criteria for opioid dependence;
  • Subject is on methadone treatment in the substitution program for at least 4 weeks;
  • Subject is aged between 18 and 65 years old;
  • subject meets the DSM-V TR criteria for major depressive episode, according to the study psychiatrist and confirmed by the Mini International Neuropsychiatric Interview (MINI);
  • Subject reports a score of 20 or higher on the MADRS;
  • Subject is eligible for and consents to the study;
  • subject is able to give valid, informed consent;
  • subject is able to speak and read French or English (grade-nine level of language required)

Exclusion Criteria:

  • Unstable medical illness, defined as any medical illness which has not been well-controlled with standard-of-care medications;
  • Severe psychiatric condition (e.g., current acute psychosis, past or current hypomania/mania) based on the MINI;
  • Pregnancy or breastfeeding;
  • Inability to use a medically acceptable form of contraception throughout the study duration. A medically acceptable form of contraception is either: (1) contraceptive pill or intrauterine device or depot hormonal preparation (ring, injection, implant); and/or (2) a barrier method of contraception such as diaphragm, sponge with spermicide or condom;
  • Subject currently takes another antidepressant;
  • Treatment with Desvenlafaxine at any time in the past;
  • Known hypersensitivity to venlafaxine;
  • Subject is undergoing psychotherapies for current depression (support therapy or counseling are allowed);
  • Subject failed to respond to two or more Health-Canada-approved antidepressants during current episode;
  • Unstable Axis-II personality disorder or other Axis-II disorder which has been the primary focus of treatment in the past 3 months, as ascertained by a study psychiatrists;
  • Medical diagnosis of kidney and/or liver failure
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02200406


Locations
Layout table for location information
Canada, Quebec
Centre de recherche du Centre Hospitalier de l'Université de Montréal
Montréal, Quebec, Canada, H2X0A9
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Didier Jutras-Aswad, M.D., M.Sc. Centre hospitalier de l'Université de Montréal (CHUM)
Study Chair: Suzanne Brissette, M.D., M.Sc. Centre hospitalier de l'Université de Montréal (CHUM)
Study Chair: Julie Bruneau, M.D., M.Sc. Centre hospitalier de l'Université de Montréal (CHUM)
Study Chair: Paul Lespérance, M.D., M.Sc. Centre hospitalier de l'Université de Montréal (CHUM)
Study Chair: Clairélaine Ouellet-Plamondon, M.D. Centre hospitalier de l'Université de Montréal (CHUM)
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM)
ClinicalTrials.gov Identifier: NCT02200406    
Other Study ID Numbers: WI187002
Pfizer Reference Award Number ( Other Grant/Funding Number: WI187002 )
First Posted: July 25, 2014    Key Record Dates
Last Update Posted: October 23, 2020
Last Verified: August 2017
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
Desvenlafaxine
Opioid-dependent
Addiction
 Depression
Methadone
Comorbidity
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Narcotic-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
 Desvenlafaxine Succinate
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents
Psychotropic Drugs